"In keeping with its efforts to make therapies accessible and affordable to patients, the drug will be highly economical, priced at 1/3rd the cost than currently available Dapagliflozin brands in India," it added.from Moneycontrol Business News https://ift.tt/3d0q74Q
No comments:
Post a Comment